InterMune’s Idiopathic Pulmonary Fibrosis Push Continues As Actimmune Sales Slump
This article was originally published in The Pink Sheet Daily
Executive Summary
Data support gambling on experimental pirfenidone against “incredibly complex” disease, chief scientific officer tells “The Pink Sheet” DAILY.
You may also be interested in...
InterMune Positive On Pirfenidone Despite Mixed Study Results
InterMune was left with a mixed bag when it released its major Phase III program of pirfenidone in idiopathic pulmonary fibrosis, which yielded conflicting primary endpoint results. But the company thinks there are enough tricks in that bag to win FDA approval
InterMune Positive On Pirfenidone Despite Mixed Study Results
InterMune was left with a mixed bag when it released its major Phase III program of pirfenidone in idiopathic pulmonary fibrosis, which yielded conflicting primary endpoint results. But the company thinks there are enough tricks in that bag to win FDA approval
InterMune Bullish On Pirfenidone NDA Despite Mixed Study Results
Differences in patient populations may explain conflicting results from Phase III pulmonary fibrosis trials.